News | Heart Failure
Medtronic plc announced the results of an analysis that reveals patients increasingly adhere to heart failure medications after they receive cardiac resynchronization therapy (CRT) devices. The analysis of more than 4,500 patients revealed that compliance with their medications increased 67 percent 24 months after receiving their CRT implants, compared to the 24 months prior to implant (p<0.001). The results were presented at the 2016 Heart Failure Society of America (HFSA) Scientific Meeting in Orlando, Fla.
September 20, 2016
News | Vascular Access
September 20, 2016 — Teleflex Inc. recently displayed its vascular access technologies and a new educational platform ...
September 20, 2016
News | Heart Valve Technology
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcatheter ...
September 20, 2016Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News | Cath Lab
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a single ...
September 19, 2016
News | Heart Valve Technology
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at PCR London Valves 2016, Sept. 18-20. In addition, updated two-year follow-up results of the multi-center Cardioband Mitral study will be presented at the meeting.
September 19, 2016
News | Heart Valve Technology
September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the company's ...
September 19, 2016Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
Technology | Drug-Eluting Balloons
Medtronic plc announced that the U.S. Food and Drug Administration (FDA) approved the IN.PACT Admiral drug-coated balloon (DCB) as a treatment for in-stent restenosis (ISR) in patients with peripheral artery disease (PAD). This is the first DCB that has gained approval to treat ISR in the United States. FDA approval was based on ISR data from the IN.PACT Global Study compared to a standard percutaneous balloon angioplasty (PTA) control.
September 19, 2016
Technology | Peripheral Artery Disease (PAD)
September 16, 2016 — The U.S. Food and Drug Administration (FDA) has granted market clearance for Shockwave Medical’s ...
September 16, 2016
Videos | Peripheral Artery Disease (PAD)
This video, provided by Shockwave Medical, demonstrates the Lithoplasty System. It uses ultrasonic waves to treatment ...
September 16, 2016Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
EBR Systems Inc. announced the U.S. Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) for its WiSE (Wireless Stimulation Endocardially) Technology for cardiac resynchronization therapy (CRT). This IDE enables EBR Systems to start a major U.S. study to establish safety and effectiveness in support of U.S. approval.
September 15, 2016
Feature | Cath Lab
Vascular Interventional Advances (VIVA) 2016 released its list late-breaking research presentations in vascular ...
September 14, 2016News | Cardiac Diagnostics
September 13, 2016 — Results from a new study suggest that small molecules known as microRNAs may be part of the pathway ...
September 13, 2016Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023News | Cardiac Diagnostics
September 13, 2016 — Findings from a small study suggest that people who followed the popular Paleo diet for only eight ...
September 13, 2016
Feature | Cardiovascular Business | John W. Meyer, MPH, FACHE
(Editor’s note: This is the first part of a two-part series on the proposed Medicare five-year demonstration for ...
September 13, 2016
News | Artificial Heart
August 29, 2016 — SynCardia Systems, manufacturer of the Total Artificial Heart (TAH), announced that the judge ...
September 13, 2016© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now